Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis
- PMID: 12760890
- PMCID: PMC155861
- DOI: 10.1128/AAC.47.6.2018-2021.2003
Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis
Abstract
The influence of reduced susceptibilities to glycopeptides on the activities of vancomycin and teicoplanin against an isogenic pair of clinical Staphylococcus aureus strains in experimental endocarditis was investigated. While vancomycin was similarly active against both strains, teicoplanin was approximately 100-fold less active against the resistant strain and selected for the emergence of more resistant subpopulations.
Figures



Similar articles
-
Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy.Antimicrob Agents Chemother. 2005 Feb;49(2):857-9. doi: 10.1128/AAC.49.2.857-859.2005. Antimicrob Agents Chemother. 2005. PMID: 15673789 Free PMC article.
-
Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Antimicrob Agents Chemother. 1994 Sep;38(9):2034-40. doi: 10.1128/AAC.38.9.2034. Antimicrob Agents Chemother. 1994. PMID: 7811015 Free PMC article.
-
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis.Antimicrob Agents Chemother. 1990 Nov;34(11):2081-5. doi: 10.1128/AAC.34.11.2081. Antimicrob Agents Chemother. 1990. PMID: 1963526 Free PMC article.
-
[Use of glycopeptides in the treatment of infections caused by methicillin-resistant staphylococci].Rev Clin Esp. 1997 Sep;197 Suppl 2:52-8. Rev Clin Esp. 1997. PMID: 9441324 Review. Spanish. No abstract available.
-
[Streptogramins and glycopeptides].Nihon Rinsho. 2007 Feb 28;65 Suppl 2 Pt. 1:360-6. Nihon Rinsho. 2007. PMID: 17455646 Review. Japanese. No abstract available.
Cited by
-
Vancomycin heteroresistance in methicillin-resistant Staphylococcus aureus, Taiwan.Emerg Infect Dis. 2004 Sep;10(9):1702-4. doi: 10.3201/eid1009.040239. Emerg Infect Dis. 2004. PMID: 15503416 Free PMC article. No abstract available.
-
Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective.Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):100-8. doi: 10.1007/s10096-004-1261-y. Eur J Clin Microbiol Infect Dis. 2005. PMID: 15682283 Review.
-
Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.Antimicrob Agents Chemother. 2004 Mar;48(3):1061-4. doi: 10.1128/AAC.48.3.1061-1064.2004. Antimicrob Agents Chemother. 2004. PMID: 14982811 Free PMC article.
-
In vivo pharmacodynamic activity of the glycopeptide dalbavancin.Antimicrob Agents Chemother. 2007 May;51(5):1633-42. doi: 10.1128/AAC.01264-06. Epub 2007 Feb 16. Antimicrob Agents Chemother. 2007. PMID: 17307987 Free PMC article.
-
Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.Tex Heart Inst J. 2010;37(4):400-4. Tex Heart Inst J. 2010. PMID: 20844611 Free PMC article.
References
-
- Aeschlimann, J. R., G. P. Allen, E. Hershberger, and M. J. Ryback. 2000. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicrob. Agents Chemother. 44:2991-2998. - PMC - PubMed
-
- Centers for Disease Control and Prevention. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin—United States, 1997. Morb. Mortal. Wkly. Rep. 46:765-766. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical